210 related articles for article (PubMed ID: 25521164)
1. The molecular spectrum and clinical impact of DIS3 mutations in multiple myeloma.
Weißbach S; Langer C; Puppe B; Nedeva T; Bach E; Kull M; Bargou R; Einsele H; Rosenwald A; Knop S; Leich E
Br J Haematol; 2015 Apr; 169(1):57-70. PubMed ID: 25521164
[TBL] [Abstract][Full Text] [Related]
2. A compendium of DIS3 mutations and associated transcriptional signatures in plasma cell dyscrasias.
Lionetti M; Barbieri M; Todoerti K; Agnelli L; Fabris S; Tonon G; Segalla S; Cifola I; Pinatel E; Tassone P; Musto P; Baldini L; Neri A
Oncotarget; 2015 Sep; 6(28):26129-41. PubMed ID: 26305418
[TBL] [Abstract][Full Text] [Related]
3.
Boyle EM; Ashby C; Tytarenko RG; Deshpande S; Wang H; Wang Y; Rosenthal A; Sawyer J; Tian E; Flynt E; Hoering A; Johnson SK; Rutherford MW; Wardell CP; Bauer MA; Dumontet C; Facon T; Thanendrarajan S; Schinke CD; Zangari M; van Rhee F; Barlogie B; Cairns D; Jackson G; Thakurta A; Davies FE; Morgan GJ; Walker BA
Clin Cancer Res; 2020 May; 26(10):2422-2432. PubMed ID: 31988198
[TBL] [Abstract][Full Text] [Related]
4.
Ohguchi Y; Ohguchi H
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835493
[TBL] [Abstract][Full Text] [Related]
5. DIS3 mutations in multiple myeloma impact the transcriptional signature and clinical outcome.
Todoerti K; Ronchetti D; Favasuli V; Maura F; Morabito F; Bolli N; Taiana E; Neri A
Haematologica; 2022 Apr; 107(4):921-932. PubMed ID: 33951891
[TBL] [Abstract][Full Text] [Related]
6. Gene-dosage dependent overexpression at the 13q amplicon identifies DIS3 as candidate oncogene in colorectal cancer progression.
de Groen FL; Krijgsman O; Tijssen M; Vriend LE; Ylstra B; Hooijberg E; Meijer GA; Steenbergen RD; Carvalho B
Genes Chromosomes Cancer; 2014 Apr; 53(4):339-48. PubMed ID: 24478024
[TBL] [Abstract][Full Text] [Related]
7. Multiple myeloma-associated hDIS3 mutations cause perturbations in cellular RNA metabolism and suggest hDIS3 PIN domain as a potential drug target.
Tomecki R; Drazkowska K; Kucinski I; Stodus K; Szczesny RJ; Gruchota J; Owczarek EP; Kalisiak K; Dziembowski A
Nucleic Acids Res; 2014 Jan; 42(2):1270-90. PubMed ID: 24150935
[TBL] [Abstract][Full Text] [Related]
8. Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma.
Pertesi M; Vallée M; Wei X; Revuelta MV; Galia P; Demangel D; Oliver J; Foll M; Chen S; Perrial E; Garderet L; Corre J; Leleu X; Boyle EM; Decaux O; Rodon P; Kolb B; Slama B; Mineur P; Voog E; Le Bris C; Fontan J; Maigre M; Beaumont M; Azais I; Sobol H; Vignon M; Royer B; Perrot A; Fuzibet JG; Dorvaux V; Anglaret B; Cony-Makhoul P; Berthou C; Desquesnes F; Pegourie B; Leyvraz S; Mosser L; Frenkiel N; Augeul-Meunier K; Leduc I; Leyronnas C; Voillat L; Casassus P; Mathiot C; Cheron N; Paubelle E; Moreau P; Bignon YJ; Joly B; Bourquard P; Caillot D; Naman H; Rigaudeau S; Marit G; Macro M; Lambrecht I; Cliquennois M; Vincent L; Helias P; Avet-Loiseau H; Moreno V; Reis RM; Varkonyi J; Kruszewski M; Vangsted AJ; Jurczyszyn A; Zaucha JM; Sainz J; Krawczyk-Kulis M; Wątek M; Pelosini M; Iskierka-Jażdżewska E; Grząśko N; Martinez-Lopez J; Jerez A; Campa D; Buda G; Lesueur F; Dudziński M; García-Sanz R; Nagler A; Rymko M; Jamroziak K; Butrym A; Canzian F; Obazee O; Nilsson B; Klein RJ; Lipkin SM; McKay JD; Dumontet C
Leukemia; 2019 Sep; 33(9):2324-2330. PubMed ID: 30967618
[No Abstract] [Full Text] [Related]
9. DIS3 isoforms vary in their endoribonuclease activity and are differentially expressed within haematological cancers.
Robinson SR; Viegas SC; Matos RG; Domingues S; Bedir M; Stewart HJS; Chevassut TJ; Oliver AW; Arraiano CM; Newbury SF
Biochem J; 2018 Jun; 475(12):2091-2105. PubMed ID: 29802118
[TBL] [Abstract][Full Text] [Related]
10. Deletion of chromosome 13q14 detected by fluorescence in situ hybridization has prognostic impact on survival after high-dose therapy in patients with multiple myeloma.
Worel N; Greinix H; Ackermann J; Kaufmann H; Urbauer E; Höcker P; Gisslinger H; Lechner K; Kalhs P; Drach J
Ann Hematol; 2001 Jun; 80(6):345-8. PubMed ID: 11475148
[TBL] [Abstract][Full Text] [Related]
11. Exonuclease domain mutants of yeast DIS3 display genome instability.
Milbury KL; Paul B; Lari A; Fowler C; Montpetit B; Stirling PC
Nucleus; 2019 Dec; 10(1):21-32. PubMed ID: 30724665
[TBL] [Abstract][Full Text] [Related]
12. A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5.
White BS; Lanc I; O'Neal J; Gupta H; Fulton RS; Schmidt H; Fronick C; Belter EA; Fiala M; King J; Ahmann GJ; DeRome M; Mardis ER; Vij R; DiPersio JF; Levy J; Auclair D; Tomasson MH
Blood Cancer J; 2018 Mar; 8(3):35. PubMed ID: 29563506
[TBL] [Abstract][Full Text] [Related]
13. Collaborative Control of Cell Cycle Progression by the RNA Exonuclease Dis3 and Ras Is Conserved Across Species.
Snee MJ; Wilson WC; Zhu Y; Chen SY; Wilson BA; Kseib C; O'Neal J; Mahajan N; Tomasson MH; Arur S; Skeath JB
Genetics; 2016 Jun; 203(2):749-62. PubMed ID: 27029730
[TBL] [Abstract][Full Text] [Related]
14. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.
Rajkumar S; Fonseca R; Lacy M; Witzig T; Lust J; Greipp P; Therneau T; Kyle R; Litzow M; Gertz M
Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations.
Chng WJ; Santana-Dávila R; Van Wier SA; Ahmann GJ; Jalal SM; Bergsagel PL; Chesi M; Trendle MC; Jacobus S; Blood E; Oken MM; Henderson K; Kyle RA; Gertz MA; Lacy MQ; Dispenzieri A; Greipp PR; Fonseca R
Leukemia; 2006 May; 20(5):807-13. PubMed ID: 16511510
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion.
Sagaster V; Ludwig H; Kaufmann H; Odelga V; Zojer N; Ackermann J; Küenburg E; Wieser R; Zielinski C; Drach J
Leukemia; 2007 Jan; 21(1):164-8. PubMed ID: 17096015
[TBL] [Abstract][Full Text] [Related]
17. Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients.
Grzasko N; Hus M; Pluta A; Jurczyszyn A; Walter-Croneck A; Morawska M; Chocholska S; Hajek R; Dmoszynska A
Hematol Oncol; 2013 Mar; 31(1):41-8. PubMed ID: 22674819
[TBL] [Abstract][Full Text] [Related]
18. Molecular cytogenetic aberrations in patients with multiple myeloma studied by interphase fluorescence in situ hybridization.
Chen L; Li J; Xu W; Qiu H; Zhu Y; Zhang Y; Duan L; Qian S; Lu H
Exp Oncol; 2007 Jun; 29(2):116-20. PubMed ID: 17704743
[TBL] [Abstract][Full Text] [Related]
19. Abnormalities of chromosome 1p/q are highly associated with chromosome 13/13q deletions and are an adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma.
Wu KL; Beverloo B; Lokhorst HM; Segeren CM; van der Holt B; Steijaert MM; Westveer PH; Poddighe PJ; Verhoef GE; Sonneveld P; ;
Br J Haematol; 2007 Feb; 136(4):615-23. PubMed ID: 17223915
[TBL] [Abstract][Full Text] [Related]
20.
Favasuli VK; Ronchetti D; Silvestris I; Puccio N; Fabbiano G; Traini V; Todoerti K; Erratico S; Ciarrocchi A; Fragliasso V; Giannandrea D; Tumiatti F; Chiaramonte R; Torrente Y; Finelli P; Morelli E; Munshi NC; Bolli N; Neri A; Taìana E
Haematologica; 2024 Jan; 109(1):231-244. PubMed ID: 37439377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
